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Abstract 
Concerns over reproducibility in science extend to research using existing healthcare data; 
many observational studies investigating the same topic produce conflicting results, even when 
using the same data. To address this problem, we propose a paradigm shift. The current 
paradigm centers on generating one estimate at a time using a unique study design with 
unknown reliability and publishing (or not) one estimate at a time.  The new paradigm 
advocates for high-throughput observational studies using consistent and standardized 
methods, allowing evaluation, calibration, and unbiased dissemination to generate a more 
reliable and complete evidence base. We demonstrate this new paradigm by comparing all 
depression treatments for a set of outcomes, producing 17,718 hazard ratios, each using 
methodology on par with state-of-the-art studies. We furthermore include control hypotheses 
to evaluate and calibrate our evidence generation process. Results show good transitivity and 
consistency between databases, and agree with four out of the five findings from clinical trials. 
The distribution of effect size estimates reported in literature reveals an absence of small or 
null effects, with a sharp cutoff at p = 0.05. No such phenomena were observed in our results, 
suggesting more complete and more reliable evidence.  
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Introduction 
Great concern exists over reproducibility in science, with many scientists even using the term 
‘reproducibility crisis’ (1). Low sample size, small effect sizes, data dredging (including P-
hacking), conflicts of interest, large numbers of scientists working competitively in silos without 
combining their efforts, and so on, may conspire to dramatically increase the probability that a 
published finding is incorrect (2). Although many solutions have been proposed, including pre-
registering studies, open science, team research, and better reporting, adoption of these 
solutions is still lacking (3, 4). Here we focus on reproducibility in observational research using 
existing health care data, where we believe a complementary solution is viable that would 
vastly improve reproducibility, while at the same time generate large amounts of reliable 
scientific evidence. 
Existing health care data, such as claims and electronic health records, hold the promise of 
providing new insights to improve patient care. These data capture details of real-world 
experiences of patients and their encounters with the health care system, allowing the study of 
many types of therapies and revealing benefits received and harm done. Certainly, there exist 
limits to the range of questions that these data can answer as they are based on interactions 
with the healthcare system and depend on accurate recording of events. There is also an 
information asymmetry as ‘harms’ tend to come to medical attention and are easily reflected in 
these data while ‘benefits’ are often neither easily reflected in these data nor do they tend to 
drive patients to clinical encounters. Observational studies are more susceptible to bias, placing 
them lower in the hierarchy of clinical evidence than randomized clinical trials. Nonetheless, 
these data could yield a wealth of insights that go well beyond what can be explored through 
other sources of evidence. 
Current observational research relies on one-off studies answering one question at a time with 
unique methodology and therefore unknown reliability, and disseminating these results (or not) 
one estimate at a time. Here we propose to unlock the potential of existing health care data by 
defining a high-throughput approach to observational research; we systematically compare all 
treatments for a given indication for a large set of outcomes captured in data from the 
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Observational Health Data Science and Informatics (OHDSI) (5) research network. We adjust for 
measured confounders using propensity score stratification, a state-of-the-art confounder-
adjustment strategy, but instead of the current practice of hand-picking covariates for the 
propensity model, we employ a completely data-driven approach to variable selection. In 
addition, uncertainty due to residual observational study bias, for example due to unmeasured 
confounders, is quantified by using control hypotheses (research questions with known 
answers). We employ both real negative control hypotheses (where the true hazard ratio is 
known to be 1) as well as synthetic positive control hypotheses (where the true hazard ratio is 
of known magnitude greater than 1), created by modifying negative controls. We subsequently 
express the observed uncertainty due to residual bias in calibrated confidence intervals (CIs) 
(6). We disseminate all results, thereby not only providing evidence at large scale, but also 
preventing publication bias. We demonstrate this new paradigm by comparing all treatments 
for depression for a large set of health outcomes using four large insurance claims databases, as 
depicted in Figure 1.  
 
Figure 1. High-throughput observational study design with empirical calibration, applied to the 
comparison of depression treatments. We apply this design to four large insurance claims 
databases.  
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We evaluate our results in terms of transitivity and between-database consistency, and 
agreement with effects known from clinical trials. We also show that our distribution of 
estimates is markedly different from the distribution observed in literature, suggesting more 
complete and more reliable evidence. 
Results 
Example single research hypothesis 
We demonstrate our high-throughput process by first showing the analysis for a single research 
question: the comparison of duloxetine to sertraline for the risk of stroke, using the Truven 
MarketScan Commercial Claims and Encounters (CCAE) database. We compare our approach to 
a previously published study by Lee et al.(7). Whereas that study compares new users of the 
entire drug classes to which these drugs belong, our analysis investigates new users of the two 
specific drugs. Both Lee et al. and our analysis require 12 months of continuous observation 
prior to treatment initiation, exclude people exposed to both drugs and people with prior 
strokes, and use stratification on the propensity score to address confounding. Follow-up is 
defined as starting on the day of treatment initiation and stopping on the day of the outcome, 
discontinuation of treatment (allowing a 30 day-gap between treatments), or disenrollment. 
Lee at al. hand-picked 74 covariates such as age, sex, and various selected drugs and diagnoses 
to create a propensity model. In contrast, we used a data-driven approach to generate a 
propensity model based on 59,038 covariates. Figure 2A shows our propensity score 
distribution across new users. 
For many subjects, treatment assignment is highly dependent upon their baseline 
characteristics, indicating that the groups are fundamentally different and that without 
adjustment there is a high likelihood of confounding. On the other hand, Figure 2A also reveals 
substantial overlap, implying that propensity score adjustment should be able to make the 
groups equivalent, at least with regard to measured covariates. Indeed, Figure 2B shows that 
many covariates are imbalanced prior to adjustment, but after stratification all covariates have 
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balance. This includes any covariates that experts might consider relevant such as comorbidities 
and current or prior medication use. 
 
 
Figure 2. Cohort comparability and balance for duloxetine versus sertraline new users from the 
CCAE database. (A) Propensity score distributions for each cohort. (B) Absolute values of the 
standardized difference of the mean before and after stratification for the 59,038 covariates 
established at baseline. 
 
For stroke risk, our analysis produces a propensity score-adjusted hazard ratio of 1.13 (95% CI: 
0.81-1.61). This result stands in agreement with Lee et al.(7) who report an adjusted hazard 
ratio of 1.01 (95% CI: 0.90-1.12). Both studies also include sensitivity analyses that consider an 
alternative time-at-risk definition and show little variation in the estimate. We argue that the 
method used in both studies is of comparable rigor, and that our analysis meets the criteria for 
peer review, demonstrated by the publication of our studies using similar designs (8-10).  
Figure 3 shows the estimates produced by applying the same analysis to a set of control 
outcomes (outcomes where the hazard ratio is known), while still comparing duloxetine to 
sertraline. This figure reveals the coverage of the uncalibrated 95% CI to be smaller than 95%. 
Calibrating the CIs using these observed operating characteristics restores near-nominal 
coverage. 
A B 
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Figure 3. Evaluation of effect estimation between duloxetine and sertraline new users after 
stratification on the propensity scores before (top) and after (bottom) calibration. Each dot 
represents the hazard ratio and corresponding standard error for one of the negative (true 
hazard ratio = 1) or positive control (true hazard ratio > 1) outcomes. 
 
Using the same calibration process, our hazard ratio for stroke becomes 1.11 (95% CI: 0.77-
1.62), compared to the uncalibrated estimate of 1.13 (95% CI: 0.81-1.61). Although these 
estimates are similar, the empirical evaluation and calibration provide confidence that 
systematic error in our calibrated estimate remains small.  
Results of all comparisons 
With four databases, the potential number of effect size estimates is (4 * 5,984 =) 23,936. We 
generate no risk estimate if at least one of the two treatment groups in a comparison contains 
less than 2,500 persons, so the final count is 17,718 estimates. The full set of results are 
available in the Supplementary Materials and can be explored online at 
http://data.ohdsi.org/SystematicEvidence. The results of our evaluation and calibration using 
control outcomes, verified by cross-validation can be found in the Supplementary Materials. 
The distribution of calibrated effect size estimates is also shown in figure 5C.  
Effect transitivity 
If drug A has a statistically significant higher risk than drug B for a particular outcome, and drug 
B has a statistically significant higher risk than C for that same outcome, we expect A to have a 
statistically significant higher risk than C. In total, we identified 755 such A-B-C combinations, of 
which for 722 triplets (96%) the transitivity property held.  
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Between-database consistency 
Our previous work has suggested remarkably high heterogeneity when uncalibrated but 
identical observational study designs are implemented in different databases (11). In the 
present context, ideally, calibrated effects estimated across the four observational databases 
would be relatively consistent. For the 2,570 target-comparator-outcome triplets having 
sufficient data in all four databases, we compute the I2 heterogeneity metric (12). An I2 of zero 
means no between-database heterogeneity is observed. Across databases, 83% of calibrated 
estimates have an I2 below 0.25; see Figure 4 for a complete histogram. In contrast, and in line 
with our previous work, only 58% of the estimates have an I2 below 0.25 when no calibration is 
applied. 
 
Figure 4. I2 distribution for all 2,570 target-comparator-outcome triplets for which there was 
enough data in all four databases. Blue shows the distribution before calibration, red shows the 
distribution after calibration.  
Consistency with established knowledge 
An additional test of validity compares our results with the current literature. Gartlehner et al. 
(13) systematically review comparative effects of antidepressant treatments based on 
randomized clinical trials (RCTs) and observational studies. Five findings emerge from the RCTs: 
1) sertraline has higher risk of diarrhea than comparators; 2) venlafaxine has higher risk of 
nausea than selective serotonin reuptake inhibitors (SSRIs); 3) there is no difference in nausea 
between duloxetine and paroxetine or fluoxetine; 4) paroxetine has higher rate of sexual 
dysfunction than fluoxetine and sertraline; and 5) bupropion has lower incidence of sexual 
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dysfunction than fluoxetine, paroxetine, and sertraline. Our result set correctly identified 
findings 1 through 4, as discussed in the Supplementary Materials—implying substantial but not 
perfect agreement with the literature. Supplementary Figure S3 also compares our results for 
finding 1 to estimates from RCTS reported in a systematic review on the topic (14), showing 
agreement as well as greater precision in our estimates due to the much larger sample size. 
Finding 5 follows from five RCTs that demonstrated a significant lower rate of sexual adverse 
events in patients exposed to bupropion relative to SSRIs. Clinical guidelines suggest bupropion 
as an alternative treatment if a patient experiences sexual side effects with an SSRI medication 
(15) and other supporting trials recommend bupropion for patients for whom sexual 
dysfunction is a concern (16). From our result set, three databases return increased risks 
associated with bupropion relative to sertraline and fluoxetine. For example, in CCAE, the 
calibrated hazard ratio for decreased libido between bupropion and sertraline new users is 1.43 
(1.09 – 1.89) and 1.42 (1.10 – 1.84) relative to fluoxetine new users. Channeling bias due to 
unmeasured baseline characteristics, such as sexual behavior, may explain this discordant 
finding.  
Comparing the distribution of estimates with the literature 
To compare our approach to the current scientific process, we show the distribution of effect 
size estimates from observational studies reported in the literature (Figure 5A), the subset of 
estimates for depression treatments (Figure 5B), and compare it against estimates produced in 
the high-throughput study described in this paper (Figure 5C). At least three observations 
emerge from the current corpus of published observational studies. First, the vast majority of 
effect estimates in literature abstracts (>80%) have a confidence interval (CI) that excludes one 
(i.e., statistically significant effects at p<0.05). One explanation posits that researchers select 
hypotheses to test that have high a priori probabilities of being true. Another explanation is 
that observational studies are vulnerable to bias, for example due to confounding, selection 
bias, and measurement error, that can easily lead to statistically significant but erroneous 
results (17). Yet another explanation is that there is a tendency to only report results when the 
CI excludes one, resulting in publication bias. This ties into our second observation: In evidence 
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reported in the literature there is a sharp boundary between the regions where the CI does and 
does not include one, suggesting that publication bias is pervasive. Third, when focusing on one 
specific area of interest (Figure 5B), in this case depression treatments, the literature is sparse 
compared to the more exhaustive approach taken in our study. Few of the questions that could 
have been asked are truly answered in literature, perhaps because the current process is too 
inefficient, slow, or because of the demonstrated publication bias. 
 
Figure 5. Effect size estimates from the literature (A, B) and the study described in this paper 
(C). Each dot represents a single estimate, such as relative risk, odds ratio, or hazard ratio, and 
corresponding standard error (linearly related to the width of the asymptotic confidence 
interval (CI)). Estimates below the red dashed line have a CI that excludes one, suggesting a 
non-null effect. Plot A shows estimates extracted from the abstracts of all observational 
research papers in MEDLINE, plot B shows only the subset of those that are related to 
depression treatments. Plot C shows estimated and calibrated hazard ratios for comparisons 
between depression treatments for various health outcomes of interest, generated from 
observational data in a single study using a systematic process. An online interactive 
visualization enables readers to explore these results in detail, including individual study 
artifacts for the estimates we generated (http://data.ohdsi.org/SystematicEvidence) 
Discussion  
The distribution of estimates extracted from the literature (Figures 5A and 5B) exposes several 
concerns: Answers to many relevant questions are missing, either because they have not yet 
been investigated, or because publication bias hides effect sizes close to or equal to one. In 
addition, evidence that is present is unreliable for two reasons. One reason is the evident 
publication bias, making a high false-positive rate likely (2). In aggregate, published 
observational research is akin to data fishing at a massive proportion; by reporting primarily 
‘statistically significant’ results and hiding others, spurious results due to random error appear 
legitimate because no adjustment is possible for the hidden multiple testing. The second reason 
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is the proliferation of observational study bias (17). Indeed, observational research literature 
stands replete with multiple studies reporting statistically significant results in conflicting 
directions, even when employing the same data (18-27).  
Applying a high-throughput observational study design can address these problems, as we have 
demonstrated in our example study comparing the effects of depression treatments: First, the 
evidence from such a study can be produced and disseminated as a single unit, and thereby 
prevent publication bias from reducing the validity of our results. Second, the inclusion of 
control hypotheses allows for evaluation of our study, measuring its operating characteristics 
such as coverage of the CI. We even use these measures to calibrate our results to restore 
nominal characteristics, as confirmed in our experimental results. Consequently, our estimates 
have a markedly different distribution compared with those found in the current literature, as 
demonstrated by comparing Figures 5A, 5B and 5C. 
Does quantity come at the cost of quality? 
A potential criticism to our approach is that addressing many research questions at once is at 
odds with thoughtful study design for any single question, and therefore likely leads to lower 
quality research. However, each of our analyses is of high quality, sufficient to pass peer review 
as demonstrated by comparing our duloxetine-sertraline-stroke example to a published study 
and our prior publications using similar designs. Similarly, our evaluation using control 
hypotheses provides further confidence in the quality of our designs and goes above and 
beyond the recent tentative calls to include negative controls in observational studies (28, 29). 
In fact, we believe unfettered freedom to customize a study for any research question is one of 
the main causes of the lack of reproducibility of observational study results, leading us to the 
situation portrayed in Figure 5A. Our challenge to the scientific community is to point out 
changes to our study design that researchers believe to be necessary when answering a 
particular question. Such changes should be evaluated objectively on their merit, for example 
using control hypotheses, and if proven to indeed improve quality, can be incorporated in a 
systematic way in the overall study design. Thus, science can move forward in a meaningful 
way, out of the current crisis.    
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Limitations 
We require our negative controls to be truly negative, but we rarely have definitive evidence of 
the absence of a causal relationship. We must assume that a lack of evidence of an effect for 
well-studied treatments and outcomes implies evidence of a lack of effect. In reality, some of 
our negative controls could prove to be positive at a future point in time. 
In our evaluation and calibration procedure we require that the controls and the hypotheses of 
interest are exchangeable in certain aspects. We address this by choosing controls with the 
same target and comparator definitions, only differing in the outcome. However, negative 
controls could exhibit different bias than the outcomes of interest. Note that we do not assume 
the biases for these controls exactly equal the biases for the outcomes of interest, rather we 
assume only that biases draw from the same distribution. Unfortunately, we do not know for 
certain that this broad assumption holds. Furthermore, our positive controls fail to reflect bias 
due to unmeasured confounding other than that present for the negative controls on which 
they were based. However, we argue that detection of bias that may not fully represent all bias 
is better than ignoring bias completely. 
A further limitation of observational research in general is that evidence can be generated only 
for those treatments and outcomes that are captured during interactions with the health care 
system and are reflected in the data. Some outcomes cannot be studied using these data. For 
example, we could not study reduction in depression symptoms as a possible outcome of 
treatment. Unmeasured confounding factors, as may have biased the estimate of the effect of 
bupropion on sexual dysfunction, remain a potential threat to the reliability of observational 
studies. 
How to use our results 
Despite the limitations of observational data, they represent a critical component in improving 
the health care evidence base. Even though depression treatments have been extensively 
studied with hundreds of clinical trials, there is still much we do not know about the 
comparative effectiveness (including safety and tolerability) of alternative treatments. Evidence 
from our observational study can provide a reference to compare what we have learned in 
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trials with what is observed in the real world. The evidence can also be a primary source when 
trials are unavailable, underpowered, or non-generalizable to the target population of interest.  
We believe that our results should be used similarly to how one would use results currently 
scattered across observational research papers in the literature, which is typically a hypothesis-
driven process. We purposely do not correct for multiple hypotheses in our results because that 
can only be done once a hypothesis or set of hypotheses is chosen. As when using results from 
literature, it is important to consider false positives when faced with multiple testing, and our 
results readily allow for adjustment for multiple testing, because we have disseminated all 
results. Note that such adjustments are not possible when using evidence scattered in 
literature, because many studies that should have been considered were never published due 
to publication bias. If readers dredge our results set looking for the most statistically significant 
ones, appropriate interpretation will require a multiplicity correction (e.g., Bonferroni or false 
discovery rate analysis). We believe that the value of our results, however, lies not in finding a 
few very significant ones, but in having available results that are poised to answer specific 
questions with as little bias as currently possible in observational research. 
Significance 
To illustrate an example from our results, consider the outcome of suicidality. All 
antidepressants have FDA product labels that contain a black boxed warning for suicidal 
thinking and behavior. However, despite the considerable attention and public health 
importance of the outcome, “evidence from existing studies is insufficient to draw conclusions 
about the comparative risk of suicidality” (13). Our results readily provide evidence on this 
question, and to demonstrate this we consider SSRIs, the most prevalent class of 
antidepressants, and compare them to amitriptyline and bupropion, two other highly prevalent 
drugs that are not SSRIs. Our results in Figure 6 suggest that SSRIs (sertraline, fluoxetine, 
citalopram, escitalopram) may have an increased risk of suicidality relative to amitriptyline and 
bupropion. Evidence for other hypotheses similarly left unanswered by clinical trials could serve 
a valuable role to inform medical decision-making when weighing the collective benefits and 
harms of alternative treatments. 
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Figure 6. Subset of hazard ratio (HR) estimates and calibrated 95% confidence intervals (CI) 
generated in our study, for the outcome of suicide or suicidal ideation.  
Improving our study 
While our choice of methods to address confounding (data-driven propensity score matching) 
and residual bias (confidence interval calibration) can be considered the current state-of-the-
art, future studies could replace these with improved methods. In fact, we sincerely hope that 
observational researchers will move their focus from performing one-off studies to refining the 
high-throughput approach as described in this paper. Rather than each researcher working in 
isolation, we hope the scientific community will come together to build the process that 
generates evidence. To facilitate this, we have made all software necessary to execute this 
study available as open source. 
Conclusion 
We propose a paradigm shift in how researchers generate and disseminate evidence from 
observational data. The current paradigm centers on generating one estimate at a time using a 
unique study design with unknown operating characteristics and publishing estimates one at a 
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time through a dissemination process with clear limitations. The new paradigm advocates for 
larger scale studies that produce concurrent results for multiple hypotheses using consistent 
and standardized methods, allowing evaluation, calibration, and unbiased dissemination to 
generate a more reliable and complete evidence base than was previously possible. The results 
are poised for answering specific questions, able to be adjusted for multiple hypotheses as 
appropriate to the question at hand. Clinicians, regulators, and other medical decision makers 
can improve the care for patients by making well-informed decisions based on this evidence, 
and every treatment a patient receives becomes the basis for further evidence. 
Materials and Methods 
Comparison of depression treatments 
As an example of our proposed high-throughput observational research we focus on the risk of 
specific outcomes across treatment choices for major depressive disorder. Depression is the 
leading cause of disability worldwide, affecting an estimated 350 million people globally (30), 
with multiple pharmacological and non-pharmacological treatments from which to choose. We 
identified 17 depression treatments to compare, and 22 outcomes of clinical interest (see Table 
1). As a result, we have 17 * (17-1) * 22 = 5,984 research questions.  
Our study follows a typical comparative effectiveness design (31),  comparing a target 
treatment (T) to a comparator treatment (C) for the risk of an outcome (O). We create 
definitions of all Ts, Cs, and Os listed in Table 1, based on clinical knowledge and our 
understanding of the databases (see Supplementary Materials), and pre-specify the rules by 
which these definitions should be adapted for any specific combination of T, C, and O. For 
example, T and C are restricted to the calendar time when both treatments were recorded in 
the database, and people with prior O are removed from both T and C. Because of the 
observational nature of the study, subjects in T may differ from subjects in C in ways that could 
bias effect estimation. We apply a commonly used confounding adjustment strategy – 
stratification by propensity scores - to make the two cohorts more comparable. We define 
time-at-risk to start on the day of treatment initiation and stop when treatment stops, allowing 
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for a 30-day gap in treatment continuation. We specify a sensitivity analysis where the time-at-
risk is defined to stop at end of observation (end of enrollment or end of study period, 
whichever comes first). Hazard ratios are estimated using a Cox proportional model conditioned 
on the propensity score strata. 
Treatments of interest Outcomes of interest 
Amitriptyline Acute liver injury 
Bupropion Acute myocardial infarction 
Citalopram Alopecia 
Desvenlafaxine Constipation 
Duloxetine Decreased libido 
Electroconvulsive therapy Delirium 
Escitalopram Diarrhea 
Fluoxetine Fracture 
Mirtazapine Gastrointestinal hemorrhage 
Paroxetine Hyperprolactinemia 
Psychotherapy Hyponatremia 
Sertraline Hypotension 
Trazodone Hypothyroidism 
Venlafaxine Insomnia 
Vilazodone Nausea 
 Open-angle glaucoma 
 Seizure 
 Stroke 
 Suicide & suicidal ideation 
 Tinnitus 
 Vent. arr. & sudden cardiac death 
  Vertigo 
Table 1. Treatments and outcomes of interest 
Propensity score stratification 
Adjustment for baseline confounders is done by fitting a propensity model and creating 
propensity scores (PS) for every pair of exposures. The propensity score is the probability of a 
subject receiving one treatment instead of the other, conditional on baseline characteristics 
(32). We create a data-driven process that entertains a large set of predefined baseline 
covariates—often tens of thousands—consistently for all combinations of T, C and O, and use 
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the data to decide which combination of these characteristics are most predictive of the 
treatment assignment. 
The following variables are included in all PS model:  
- Demographics (age in 5-year increments, gender, race, ethnicity, year of index date, 
month of index date) 
- Condition occurrence (one or more variables per diagnose code) 
- Condition era (one or more variables per diagnose code) 
- Condition group (one or more variables per MedDRA group or SNOMED groups) 
- Drug exposure (one or more variables per drug code) 
- Drug era (one or more variables per RxNorm ingredient) 
- Drug group (one or more variables per ATC group) 
- Procedure occurrence (one or more variables per procedure code) 
- Observations (one or more variables per observation concept ID) 
- Measurements (one or more variables per measurement concept ID, including variables 
for within / above / below normal range) 
- Risk scores (including Charlson, DCSI, CHADS2, CHADS2VASc) 
Variables with less than 100 non-zero values are discarded. For full details on the covariates 
used in our models please refer to FeatureExtraction package 
(https://github.com/OHDSI/FeatureExtraction) 
The PS models are fitted using L1 regularized regression (33), using 10-fold cross-validation to 
select the regularization parameter. These PS are used to stratify the target and comparator 
cohorts in 10 strata, and the proportional hazards outcome models are conditioned on the 
strata (32). 
Control hypotheses 
We evaluate our process by applying it to research hypotheses where the truth is known with a 
high degree of certainty. Such a gold standard should include both negative and positive 
controls.  
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For comparative effectiveness studies, we define negative controls as TCO combinations where 
neither T nor C causes O and where therefore the true hazard ratio is equal to one. In practice, 
we identify negative controls by selecting exposures and outcomes that are well-studied, but 
for which no evidence in the literature or elsewhere suggests a relationship. For example, one 
negative control outcome is ‘ingrown nail’, because we firmly believe that no depression 
treatment causes ingrown nails. It is important to note that although there is no causal 
relationship, some antidepressants may be associated with ingrown nails, for example because 
the treatment is prescribed primarily for the elderly, where this condition is more prevalent. 
This allows us to test whether our confounding adjustment can correct for this confounding 
association, and produce estimates consistent with the null.  
A candidate list of negative control outcomes was generated by identifying outcomes with no 
evidence of being causally related to any exposure of interest (34). This evidence was searched 
in literature through MeSH headings (35) and natural language processing (36), spontaneous 
reports of adverse events (37), and product labels in the US (38) and Europe (39). The candidate 
outcomes were then reverse sorted by prevalence in the observational databases and manually 
curated until a reasonably-sized set of negative controls was established. The final list of 52 
negative control outcomes is provided in Table 2. 
Positive controls in this case are outcomes believed to be caused by one exposure, but not the 
other. Unfortunately, real positive controls for observational research tend to be problematic 
for three reasons: First, when comparing the effect of two treatments there often is a paucity 
of positive controls relevant for that specific comparison. Second, even if positive controls are 
available, the magnitude of the effect size may not be known with great accuracy, and often 
depends on the population in which it is measured. Third, when treatments are widely known 
to cause a particular outcome, this will shape the behavior of physicians prescribing the 
treatment, for example by taking actions to mitigate the risk of unwanted outcomes, thereby 
rendering the positive controls useless as a means for evaluation (40). We therefore use 
synthetic positive controls (6), created by modifying a negative control through injection of 
additional, simulated occurrences of the outcome. To preserve (measured) confounding, 
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simulated outcome occurrences are sampled from the probability distribution derived from a 
predictive model fitted on the data. These models use the same covariates as the propensity 
models as independent variables, and the occurrence of the negative control outcomes as the 
dependent variables. Target true hazard ratios for the positive control synthesis are 1.5, 2, and 
4, so using the 52 negative controls we are able to construct 52 * 3 = 156 positive control 
outcomes for every comparison of two treatments. No negative control outcome model is 
fitted and no positive controls are created if there were less than 100 persons with the 
outcome across all exposures. No injection is performed if, for the exposure that is considered 
for injection, there were less than 25 persons with the outcome before injection. 
Acariasis Ingrowing nail 
Amyloidosis Iridocyclitis 
Ankylosing spondylitis Irritable bowel syndrome 
Aseptic necrosis of bone Lesion of cervix 
Astigmatism Lyme disease 
Bell's palsy Malignant neoplasm of endocrine gland 
Benign epithelial neoplasm of skin Mononeuropathy 
Chalazion Onychomycosis 
Chondromalacia Osteochondropathy 
Crohn's disease Paraplegia 
Croup Polyp of intestine 
Diabetic oculopathy Presbyopia 
Endocarditis Pulmonary tuberculosis 
Endometrial hyperplasia Rectal mass 
Enthesopathy Sarcoidosis 
Epicondylitis Scar 
Epstein-Barr virus disease Seborrheic keratosis 
Fracture of upper limb Septic shock 
Gallstone Sjogren's syndrome 
Genital herpes simplex Tietze's disease 
Hemangioma Tonsillitis 
Hodgkin's disease Toxic goiter 
Human papilloma virus infection Ulcerative colitis 
Hypoglycemic coma Viral conjunctivitis 
Hypopituitarism Viral hepatitis 
Impetigo Visceroptosis 
Table 2. Negative control outcomes. Outcomes not believed to be caused by any of the 
exposures of interest. 
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With a gold standard in place, we evaluate whether our process produces results in line with 
the gold standard effect sizes. Importantly, we estimate CI coverage probability – the 
proportion of time that the CI contains the true value of interest. For example, we expect a 95% 
CI to cover the truth 95% of the time. We also apply a calibration procedure described 
elsewhere (6) that attempts to restore nominal coverage by adjusting the CIs, similarly to how 
one would calibrate a scale by using objects of known weight. In short, this procedure first 
estimates the distribution of systematic error using the observed estimates for negative and 
positive controls. We assume this distribution is Gaussian with a mean and log standard 
deviation linearly related to the true effect size. Using the estimated distribution, we then 
generate calibrated CIs considering both random and systematic error. Typically, but not 
necessarily, the calibrated CI is wider than the nominal CI, reflecting the problems unaccounted 
for in the standard procedure (such as unmeasured confounding, selection bias, and 
measurement error) but accounted for in the calibration.  
Observational databases 
The analyses have been performed across a network of observational healthcare databases. All 
databases have been transformed into the OMOP Common Data Model, version 5. The 
complete specification for OMOP Common Data Model, version 5 is available at: 
https://github.com/OHDSI/CommonDataModel. The following databases have been included in 
this analysis: 
• Truven MarketScan Commercial Claims and Encounters (CCAE) 
• Truven MarketScan Medicare Supplemental Beneficiaries (MDCR) 
• Truven MarketScan Multi-state Medicaid (MDCD) 
• OptumInsight’s de-identified ClinformaticsTM  Datamart (Optum) 
Truven MarketScan Commercial Claims and Encounters (CCAE) 
CCAE is an administrative health claims database for active employees, early retirees, COBRA 
continues, and their dependents insured by employer-sponsored plans (individuals in plans or 
product lines with fee-for-service plans and fully capitated or partially capitated plans). As of 1 
November 2016, CCAE contained 131 million patients with patient-level observations from 
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January 2000 through July 2016. Source codes used in CCAE include: conditions- ICD-9-CM; 
drugs: NDC, HCPCS, ICD-9-CM; procedures: CPT-4, HCPCS, ICD-9-CM; lab: LOINC.  
The ETL specification for transforming CCAE into the OMOP CDM is available at: 
https://github.com/OHDSI/ETL-CDMBuilder/tree/master/man/TRUVEN_CCAE_MDCR 
Truven MarketScan Medicare Supplemental Beneficiaries (MDCR) 
MDCR is an administrative health claims database for Medicare-eligible active and retired 
employees and their Medicare-eligible dependents from employer-sponsored supplemental 
plans (predominantly fee-for-service plans). Only plans where both the Medicare-paid amounts 
and the employer-paid amounts were available and evident on the claims were selected for this 
database. As of 1 November2016, MDCR contained 9.6 million patients with patient-level 
observations from January 2000 through July 2016. Source codes used in MDCR include: 
conditions- ICD-9-CM; drugs: NDC, HCPCS, ICD-9-CM; procedures: CPT-4, HCPCS, ICD-9-CM; lab: 
LOINC.  
The ETL specification for transforming MDCR into the OMOP CDM is available at: 
https://github.com/OHDSI/ETL-CDMBuilder/tree/master/man/TRUVEN_CCAE_MDCR 
Truven MarketScan Multi-state Medicaid (MDCD) 
MDCD is an administrative health claims database for the pooled healthcare experience of 
Medicaid enrollees from multiple states. As of 1 November 2016, MDCD contained 21.6 million 
patients with patient-level observations from January 2006 through Dec ember 2014. Source 
codes used in MDCD include: conditions- ICD-9-CM; drugs: NDC, HCPCS, ICD-9-CM; procedures: 
CPT-4, HCPCS, ICD-9-CM; lab: LOINC.  
The ETL specification for transforming MDCD into the OMOP CDM is available at: 
https://github.com/OHDSI/ETL-CDMBuilder/tree/master/man/TRUVEN_MDCD 
OptumInsight’s de-identified ClinformaticsTM  Datamart (Optum) 
OptumInsight’s de-identified ClinformaticsTM  Datamart (Eden Prairie,MN) is an administrative 
health claims database for members of United Healthcare, who enrolled in commercial plans 
(including ASO, 36.31M), Medicaid (prior to July 2010, 1.25M) and Legacy Medicare Choice 
21 
 
(prior to January 2006, 0.36M) with both medical and prescription drug coverage. As of 1 
November2016, Optum contained 74.7 million patients with patient-level observations from 
June 2000 through June 2016. Source codes used in Optum include: conditions- ICD-9-CM; 
drugs: NDC, HCPCS, ICD-9-CM; procedures: CPT-4, HCPCS, ICD-9-CM; lab: LOINC.  
The ETL specification for transforming Optum into the OMOP CDM is available at: 
https://github.com/OHDSI/ETL-CDMBuilder/tree/master/man/OPTUM_EXTENDED 
Extraction from literature 
Citations of observational studies were identified in PubMed using the following query:  
("population-based" [Title/Abstract] OR observational [Title/Abstract] OR 
pharmacoepidemiology [Title/Abstract]) AND (("Cohort Studies" [MeSH] OR 
"cohort" [Title/Abstract] OR "propensity score" [Title/Abstract]) OR ("Case-
Control Studies" [MeSH] OR "case control" [Title/Abstract]) OR ("self 
controlled case series" [Title/Abstract] OR ("sccs" [Title/Abstract] AND 
"self-controlled" [Title/Abstract])) OR ("case-crossover" [Title/Abstract]) ) 
AND ("1900/01/01"[PDAT]:"3000/12/31"[PDAT]) 
 
In total, 102,874 citations were retrieved. The abstracts were automatically scanned for 
occurrences of the following regular expression: 
"("+emPattern+" ?\\(|\\([^)]*"+emPattern+")[^(]*("+pValuePattern+"|"+ciPatter
n+")[^(]*\\)" 
 
where 
numberPattern = "[0-9][0-9]?[0-9]?\\.[0-9][0-9]?[0-9]?" 
emPattern = "(odds ratio|o.r.|or|relative risk|r.r.|rr|hazard 
ratio|h.r.|hr|hazard|rate ratio)([^0-9a-z]*| is | of )"+numberPattern 
pValuePattern = "p ?[<=>] ?0?\\.[0-9][0-9]?[0-9]?" 
ciPattern = numberPattern+" ?(-|to|,) ?" +numberPattern 
 
In total, 59,196 estimates were found in 24,027 abstracts. The standard error was computed 
from either the confidence interval or p-value that was found in combination with an effect size 
estimate. If both a p-value and confidence interval were present, the confidence interval was 
used. The full list of estimates is provided in the supplementary materials (Data S2). To remove 
visual artifacts due to rounding, for visualization purposes only random noise was added to the 
estimates, confidence intervals, and p-values so that the noisy numbers would still round to the 
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numbers reported in the abstracts. For example, a hazard ratio of 1.5 was converted to a 
random number between 1.450000001 and 1.549999999. 
A subset of articles related to depression treat was identified using the PubMed query:  
 
(depression OR antidepressant) AND ("serotonin reuptake inhibitors" OR 
"tricyclic antidepressant" OR Bupropion OR Mirtazapine OR Trazodone OR 
Desvenlafaxine OR duloxetine OR venlafaxine OR Citalopram OR Escitalopram OR 
Fluoxetine OR Paroxetine OR Sertraline OR vilazodone OR Amitriptyline OR  
Doxepin OR Nortriptyline or psychotherapy or "electroconvulsive therapy"). 
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Document S1. Exposure definitions 
The target and comparator groups consisted of new users of the treatments listed in Table 1, 
which are identified using the codes specified in tables S1.1-S1.4. For both cohorts we restrict 
to people with a prior diagnosis of depression, and no prior history of bipolar disorder or 
schizophrenia.  
Concept ID Concept Name 
4152280 Major depressive disorder 
435783 Schizophrenia 
436665 Bipolar disorder 
Table S1.1. Concepts used to identify prior history of depression, schizophrenia, and bipolar 
disorders. All descendants of these concepts are also considered. 
 
Concept ID RxNorm ID Concept Name 
710062 704 Amitriptyline 
750982 42347 Bupropion 
797617 2556 Citalopram 
717607 734064 Desvenlafaxine 
738156 3638 Doxepin 
715259 72625 duloxetine 
715939 321988 Escitalopram 
755695 4493 Fluoxetine 
725131 15996 Mirtazapine 
721724 7531 Nortriptyline 
722031 32937 Paroxetine 
739138 36437 Sertraline 
703547 10737 Trazodone 
743670 39786 venlafaxine 
40234834 1086769 vilazodone 
Table S1.2. The 15 included drugs and their concept identifiers. All descendants of these 
concepts are also considered. 
 
Concept ID Concept Name 
4119335 Analytical psychology 
4084202 Anti-criminal psychotherapy 
4079608 Anti-suicide psychotherapy 
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4048385 Brief group psychotherapy 
4295027 Brief solution focused psychotherapy 
4299728 Client-centered psychotherapy 
4164790 Conjoint psychotherapy 
4208314 Couple psychotherapy 
4083706 Crisis intervention 
4083131 Daily life psychotherapy 
4121662 Developmental psychodynamic psychotherapy 
4226276 Eclectic psychotherapy 
4258834 Educational psychotherapy 
4148765 Encounter group therapy 
2007747 Exploratory verbal psychotherapy 
4137086 Expressed emotion family therapy 
4048387 Expressive psychotherapy 
4173581 Extended family therapy 
46286403 Family intervention for psychosis 
2213546 Family psychotherapy (conjoint psychotherapy) (with patient present) 
4028920 Family psychotherapy procedure 
46286330 Focal psychodynamic therapy 
4226275 Formal psychological therapy 
45765516 Functional family therapy 
4079939 Functional psychotherapy 
4079500 General psychotherapy 
4117915 Generic Jungian-based therapy 
4100341 Group analytical psychotherapy 
44808677 Group cognitive behavioural therapy 
4136352 Group marathon therapy 
4268909 Group primal therapy 
4296166 Group psychotherapy 
2213548 Group psychotherapy (other than of a multiple-family group) 
2617477 Group psychotherapy other than of a multiple-family group, in a partial hospitalization 
setting, approximately 45 to 50 minutes 
4196062 Group reassurance 
2213554 Individual psychophysiological therapy incorporating biofeedback training by any 
modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, 
behavior modifying or supportive psychotherapy); 30 minutes 
2213555 Individual psychophysiological therapy incorporating biofeedback training by any 
modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, 
behavior modifying or supportive psychotherapy); 45 minutes 
4088889 Individual psychotherapy 
2007730 Individual psychotherapy 
4103512 Interactive group medical psychotherapy 
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2617478 Interactive group psychotherapy, in a partial hospitalization setting, approximately 45 
to 50 minutes 
4221997 Interactive individual medical psychotherapy 
40482841 Interpersonal psychotherapy 
4119334 Jungian-based therapy 
4118797 Long-term exploratory psychotherapy 
4118798 Long-term psychodynamic psychotherapy 
44792695 Marital psychotherapy 
2213547 Multiple-family group psychotherapy 
4118800 Narrative family psychotherapy 
4242119 Occupational social therapy 
2007749 Other individual psychotherapy 
2007750 Other psychotherapy and counselling 
45887728 Other Psychotherapy Procedures 
45763911 Parent-infant psychotherapy 
2007746 Play psychotherapy 
4083133 Potential suicide care 
4084195 Provocative therapy 
2213544 Psychoanalysis 
2007731 Psychoanalysis 
4114491 Psychoanalytic and psychodynamic therapy 
4202234 Psychodrama 
2007763 Psychodrama 
4199042 Psychodynamic psychotherapy 
4128268 Psychodynamic-interpersonal psychotherapy 
4118801 Psychotherapeutic approaches using specific settings 
4327941 Psychotherapy 
4083129 Psychotherapy - behavioral 
4079938 Psychotherapy - cognitive 
45889353 Psychotherapy for crisis 
45888237 Psychotherapy for Crisis Services and Procedures 
43527991 Psychotherapy for crisis; each additional 30 minutes (List separately in addition to 
code for primary service) 
43527990 Psychotherapy for crisis; first 60 minutes 
45887951 Psychotherapy Services and Procedures 
2108571 Psychotherapy services provided (MDD, MDD ADOL) 
43527986 Psychotherapy, 30 minutes with patient and/or family member 
43527987 Psychotherapy, 30 minutes with patient and/or family member when performed with 
an evaluation and management service (List separately in addition to the code for 
primary procedure) 
43527904 Psychotherapy, 45 minutes with patient and/or family member 
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43527988 Psychotherapy, 45 minutes with patient and/or family member when performed with 
an evaluation and management service (List separately in addition to the code for 
primary procedure) 
43527905 Psychotherapy, 60 minutes with patient and/or family member 
43527989 Psychotherapy, 60 minutes with patient and/or family member when performed with 
an evaluation and management service (List separately in addition to the code for 
primary procedure) 
4148398 Psychotherapy/sociotherapy 
4083130 Rehabilitation for disabling psychiatric problem 
44791916 Relationship psychosexual therapy 
4265313 Relationship psychotherapy 
4084201 Samaritans advisory service 
4233181 Sensate focus technique 
4272803 Sexual psychotherapy 
4035812 Sexual psychotherapy, female therapist - female patient 
4012488 Sexual psychotherapy, female therapist - male patient 
4132436 Sexual psychotherapy, group 
4143316 Sexual psychotherapy, group, all female 
4219683 Sexual psychotherapy, group, all male 
4151904 Sexual psychotherapy, group, male and female 
4278094 Sexual psychotherapy, male therapist - female patient 
4249602 Sexual psychotherapy, male therapist - male patient 
4234476 Sexual surrogate therapy 
4179241 Short-term psychodynamic therapy 
4234402 Social psychotherapy 
4128406 Specific task orientated psychotherapy 
4080044 Stimulative psychotherapy 
4262582 Structural family psychotherapy 
4263758 Structural psychotherapy 
4126653 Supportive expressive psychodynamic psychotherapy 
4311943 Supportive verbal psychotherapy 
2007748 Supportive verbal psychotherapy 
4225728 Suppressive psychotherapy 
4080048 Therapeutic psychology 
44808259 Therapeutic role play 
Table S1.3. Concepts used to identify psychotherapy.  
 
Concept ID Concept Name 
4111663 Bilateral electroconvulsive therapy 
4030840 Electroconvulsive therapy 
2108578 Electroconvulsive therapy (ECT) provided (MDD) 
2213552 Electroconvulsive therapy (includes necessary monitoring) 
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4020981 Electronarcosis 
4210144 First treatment in a course of electroconvulsive therapy 
4336318 Multiple electroconvulsive therapy 
4332436 Multiple monitored electroconvulsive therapy 
2007728 Other electroshock therapy 
44508134 Other specified electroconvulsive therapy 
2108579 Patient referral for electroconvulsive therapy (ECT) documented (MDD) 
2007727 Subconvulsive electroshock therapy 
4004830 Subconvulsive electroshock therapy 
4210145 Subsequent treatment in a course of electroconvulsive therapy 
Table S1.4. Concepts used to identify electroconvulsive therapy. 
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Document S2. Outcome definitions 
This section describes the algorithms we use to identify occurrences of the 22 outcomes of 
interest. The algorithms are framed in the context of the OMOP Common Data Model11 (CDM) 
version 5. The CDM uses a standardized terminology for encoding all information. For more 
information on the CDM and the standard vocabulary see http://ohdsi.org. The computer-
executable version of these algorithms is part of the study R package: 
https://github.com/OHDSI/StudyProtocols/tree/master/LargeScalePopEst 
Acute liver injury 
Note: This algorithm uses the set of codes identified by Udo et al. 12 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of acute liver injury1 
o for the first time in the person's history 
o visit occurrence is any of: Emergency Room Visit, Inpatient Visit 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
For people matching the Primary Events, include: 
Having all of the following criteria: 
• exactly 0 occurrences of a condition occurrence of acute liver injury exclusion concepts2 
starting between 365 days Before and 60 days After event index date 
Limit cohort of initial events to: earliest event per person. 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. acute liver injury 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
200763 Chronic hepatitis Condition SNOMED YES YES NO 
377604 Hepatic coma Condition SNOMED NO YES NO 
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Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
196029 Hepatic coma due to viral hepatitis Condition SNOMED YES YES NO 
4337543 Hepatic necrosis Condition SNOMED NO YES NO 
194087 Hepatitis due to infection Condition SNOMED YES YES NO 
196455 Hepatorenal syndrome Condition SNOMED NO YES NO 
194990 Inflammatory disease of liver Condition SNOMED NO YES NO 
4291005 Viral hepatitis Condition SNOMED YES YES NO 
 
2. acute liver injury exclusion concepts 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
192956 Cholecystitis Condition SNOMED NO YES NO 
200763 Chronic hepatitis Condition SNOMED NO YES NO 
4212540 Chronic liver disease Condition SNOMED NO YES NO 
197917 Disorder of biliary tract Condition SNOMED NO YES NO 
192353 Disorder of gallbladder Condition SNOMED NO YES NO 
192963 Disorder of pancreas Condition SNOMED NO YES NO 
196456 Gallstone Condition SNOMED NO YES NO 
4130518 Neoplasm of liver Condition SNOMED NO YES NO 
4291005 Viral hepatitis Condition SNOMED NO YES NO 
Acute myocardial infarction 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Acute MI1 
o for the first time in the person's history 
o condition type is any of: Inpatient detail - primary, Inpatient header - primary, 
Primary Condition, Inpatient detail - 1st position, Inpatient header - 1st position 
o visit occurrence is any of: Emergency Room Visit, Inpatient Visit 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Acute MI 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
4329847 Myocardial infarction Condition SNOMED NO YES NO 
314666 Old myocardial infarction Condition SNOMED YES YES NO 
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Alopecia 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Alopecia1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Alopecia 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
133280 Alopecia Condition SNOMED NO YES NO 
133959 Syphilitic alopecia Condition SNOMED YES YES NO 
Constipation 
Note: This algorithm requires the occurrence of 2 or more diagnoses, as recommended by 
Mody et al. 13 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Constipation1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Constipation 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
75860 Constipation Condition SNOMED NO YES NO 
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Decreased libido 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Decreased libido1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Decreased libido 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
436246 Reduced libido Condition SNOMED NO YES NO 
Delirium 
Note: This algorithm relies on diagnosis codes associated with hospitalization. This approach 
may lead to underreporting, as described by McCoy et al. 14 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Delirium1 
o for the first time in the person's history 
o visit occurrence is any of: Emergency Room Visit, Inpatient Visit 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Delirium 
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Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
377830 Alcohol withdrawal delirium Condition SNOMED YES YES NO 
373995 Delirium Condition SNOMED NO YES NO 
Diarrhea 
Note: This algorithm follows Broder et al. 15 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Diarrhea1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Diarrhea 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
196523 Diarrhea Condition SNOMED NO YES NO 
80141 Functional diarrhea Condition SNOMED NO YES NO 
Fracture 
Note: This algorithm follows Lanteigne et al. 16 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Fracture1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
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Appendix 1: Concept Set Definitions 
 
1. Fracture 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
435093 Closed fracture of femur Condition SNOMED NO YES NO 
441974 Closed fracture of forearm Condition SNOMED NO YES NO 
4230399 Closed fracture of hip Condition SNOMED NO YES NO 
441422 Closed fracture of humerus Condition SNOMED NO YES NO 
439166 Closed fracture of radius Condition SNOMED NO YES NO 
4278672 Fracture of forearm Condition SNOMED NO YES NO 
442619 Fracture of humerus Condition SNOMED NO YES NO 
433856 Fracture of neck of femur Condition SNOMED NO YES NO 
4131595 Fracture of radius Condition SNOMED NO YES NO 
73571 Pathological fracture Condition SNOMED NO YES NO 
Gastrointestinal hemhorrage 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Gastrointestinal hemorrhage1 
o for the first time in the person's history 
o condition type is any of: Inpatient detail - primary, Inpatient header - primary, 
Primary Condition, Inpatient detail - 1st position, Inpatient header - 1st position 
o visit occurrence is any of: Emergency Room Visit, Inpatient Visit 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Gastrointestinal hemorrhage 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
4280942 Acute gastrojejunal ulcer with perforation Condition SNOMED NO YES NO 
28779 Bleeding esophageal varices Condition SNOMED NO YES NO 
198798 Dieulafoy's vascular malformation Condition SNOMED NO YES NO 
4112183 
Esophageal varices with 
bleeding, associated with 
another disorder 
Condition SNOMED NO YES NO 
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Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
194382 External hemorrhoids Condition SNOMED NO NO NO 
192671 Gastrointestinal hemorrhage Condition SNOMED NO YES NO 
196436 Internal hemorrhoids Condition SNOMED NO NO NO 
4338225 Peptic ulcer with perforation Condition SNOMED NO YES NO 
194158 Perinatal gastrointestinal hemorrhage Condition SNOMED YES YES NO 
Hyperprolactinemia 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Hyperprolactinemia1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Hyperprolactinemia 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
4030186 Hyperprolactinemia Condition SNOMED NO YES NO 
Hyponatremia 
Note: The algorithm here relies on the recording of diagnoses codes, and might not have high 
sensitivity as remarked by Shea et al. 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Hyponatremia1 
o for the first time in the person's history 
• a measurement of Serum sodium2 
o for the first time in the person's history 
o with value as number < 136 
o unit is any of: millimole per liter 
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with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Hyponatremia 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
435515 Hypo-osmolality and or hyponatremia Condition SNOMED NO YES NO 
 
2. Serum sodium 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
3032987 
Sodium [Moles/volume] 
corrected for glucose in 
Serum or Plasma 
Measurement LOINC NO YES NO 
46235784 
Sodium [Moles/volume] 
in Serum, Plasma or 
Blood 
Measurement LOINC NO YES NO 
3019550 Sodium serum/plasma Measurement LOINC NO YES NO 
Hypotension 
Note: This algorithm follows Wernli et al. 17 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Hypotension1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Hypotension 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
4120275 Drug-induced hypotension Condition SNOMED NO YES NO 
317002 Low blood pressure Condition SNOMED NO YES NO 
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Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
314432 Maternal hypotension syndrome Condition SNOMED YES YES NO 
319041 Orthostatic hypotension Condition SNOMED NO YES NO 
Hypothyroidism 
Note: This algorithm requires the occurrences of 2 more diagnose codes, as recommended by 
Lu et al. 18 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Hypothyroidism1 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: all events per person. 
 
For people matching the Primary Events, include: 
Having all of the following criteria: 
• at least 2 occurrences of a condition occurrence of Hypothyroidism1 
starting between 0 days Before and 90 days After event index date 
Limit cohort of initial events to: earliest event per person. 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Hypothyroidism 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
140673 Hypothyroidism Condition SNOMED NO YES NO 
Insomnia 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Insomnia1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
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Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Insomnia 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
439708 Disorders of initiating and maintaining sleep Condition SNOMED NO YES NO 
436962 Insomnia Condition SNOMED NO YES NO 
4305303 Sleep deprivation Condition SNOMED NO YES NO 
Nausea 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Nausea1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Nausea 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
30284 Motion sickness Condition SNOMED YES YES NO 
31967 Nausea Condition SNOMED NO YES NO 
Open-angle glaucoma 
Note: This algorithm follows Stein et al. 19 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Open-angle glaucoma1 
o for the first time in the person's history 
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with continuous observation of at least 365 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
For people matching the Primary Events, include: 
Having all of the following criteria: 
• at least 1 occurrences of a condition occurrence of Open-angle glaucoma1 
o provider specialty is any of: Ophthalmology, Optometry, Optician 
starting between 1 days After and 365 days After event index date 
Limit cohort of initial events to: earliest event per person. 
Limit qualifying cohort to: all events per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Open-angle glaucoma 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
432908 Glaucomatocyclitic crisis Condition SNOMED YES YES NO 
441561 Low tension glaucoma Condition SNOMED NO YES NO 
4216823 Open angle with borderline findings Condition SNOMED YES YES NO 
441284 Open-angle glaucoma Condition SNOMED NO YES NO 
4072218 Secondary open-angle glaucoma Condition SNOMED YES YES NO 
Seizure 
Note: This algorithm requires either inpatient or emergency room visits as recommended by 
Wu et al. 20 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Seizure and seizure disorder1 
o for the first time in the person's history 
o visit occurrence is any of: Emergency Room Visit, Inpatient Visit 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
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Appendix 1: Concept Set Definitions 
 
1. Seizure and seizure disorder 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
380533 Convulsions in the newborn Condition SNOMED YES YES NO 
45757050 Epilepsy in mother complicating pregnancy Condition SNOMED YES YES NO 
377091 Seizure Condition SNOMED NO YES NO 
4029498 Seizure disorder Condition SNOMED NO YES NO 
Stroke 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Ischemic stroke1 
o for the first time in the person's history 
o visit occurrence is any of: Inpatient Visit 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Ischemic stroke 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
374060 Acute ill-defined cerebrovascular disease Condition SNOMED NO YES NO 
4108356 
Cerebral infarction due to 
embolism of cerebral 
arteries 
Condition SNOMED NO YES NO 
4110192 
Cerebral infarction due to 
thrombosis of cerebral 
arteries 
Condition SNOMED NO YES NO 
4043731 Infarction - precerebral Condition SNOMED NO YES NO 
Suicide and suicidal ideation 
Note: This algorithm is based on the review by Callagan et al. 21 
Initial Event Cohort 
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People having any of the following:  
 
• a condition occurrence of Suicide and suicidal ideation1 
o for the first time in the person's history 
• an observation of Suicide and suicidal ideation1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Suicide and suicidal ideation 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
439235 Self inflicted injury Condition SNOMED NO YES NO 
4181216 Self-administered poisoning Condition SNOMED NO YES NO 
444362 Suicidal deliberate poisoning Condition SNOMED NO YES NO 
4273391 Suicidal thoughts Condition SNOMED NO YES NO 
440925 Suicide Observation SNOMED NO YES NO 
 
Tinnitus 
Note: This algorithm follows Lee et al. 22 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Tinnitus1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
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Appendix 1: Concept Set Definitions 
 
1. Tinnitus 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
377575 Tinnitus Condition SNOMED NO YES NO 
Ventricular arrhythmia and sudden cardiac death 
Note: This algorithm follows the definition used by Leonard et al. 23 
Initial Event Cohort 
People having any of the following:  
 
• a condition occurrence of Ventricular arrhythmia and sudden cardiac death1 
o for the first time in the person's history 
o condition type is any of: Inpatient detail - primary, Inpatient header - primary, 
Primary Condition, Carrier claim detail - 1st position, Carrier claim header - 1st 
position, Inpatient detail - 1st position, Inpatient header - 1st position, Outpatient 
detail - 1st position, Outpatient header - 1st position 
o visit occurrence is any of: Emergency Room Visit, Inpatient Visit 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Ventricular arrhythmia and sudden cardiac death 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
321042 Cardiac arrest Condition SNOMED NO YES NO 
442289 
Death in less than 24 
hours from onset of 
symptoms 
Observation SNOMED NO YES NO 
441139 Instantaneous death Observation SNOMED NO YES NO 
4132309 Sudden death Observation SNOMED NO YES NO 
4185572 Ventricular arrhythmia Condition SNOMED NO YES NO 
437894 Ventricular fibrillation Condition SNOMED NO YES NO 
4103295 Ventricular tachycardia Condition SNOMED NO YES NO 
Vertigo 
Initial Event Cohort 
People having any of the following:  
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• a condition occurrence of Vertigo1 
o for the first time in the person's history 
with continuous observation of at least 0 days prior and 0 days after event index date, and limit 
initial events to: earliest event per person. 
 
Limit qualifying cohort to: earliest event per person. 
No end date strategy selected. By default, the cohort end date will be the end of the observation 
period that contains the index event. 
 
Appendix 1: Concept Set Definitions 
 
1. Vertigo 
Concept Id Concept Name Domain Vocabulary Excluded Descendants Mapped 
78162 Peripheral vertigo Condition SNOMED NO YES NO 
439383 Vertigo Condition SNOMED NO YES NO 
381035 Vertigo of central origin Condition SNOMED NO YES NO 
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Document S3. Consistency with gold standard from randomized controlled trials 
Sertraline increases risk of diarrhea relative to comparators: Across all four databases, we 
consistently observe sertraline having an increased risk of diarrhea relative to most comparator 
treatments, with the magnitude of effect estimates ranging from 20% to 100% increased risk.  
In MDCR, we produce estimates for 11 comparisons with sertraline, 10 of which yield calibrated 
95% confidence intervals greater than 1: nortriptyline HR=2.10 (95% CI: 1.51-2.91); 
psychotherapy HR=1.96 (95% CI: 1.22-3.41); fluoxetine HR=1.71 (95% CI: 1.34-2.20); sertraline 
HR=1.68 (95% CI: 1.44-1.97); venlafaxine HR=1.58 (95% CI: 1.35-1.86); amitriptyline HR=1.56 
(95% CI: 1.10-2.37); duloxetine HR=1.33 (95% CI: 1.09-1.68); trazodone HR=1.33 (95% CI: 1.12-
1.59); citalopram HR=1.31 (95% CI: 1.15-1.49); escitalopram HR=1.22 (95% CI: 1.07-1.40); and 
mirtazapine HR=1.16 (95% CI: 0.98-1.38). All comparisons in MDCR except psychotherapy pass 
all empirical diagnostics, with sufficient sample near clinical equipoise, adequate covariate 
balance, and empirical calibration demonstrating nominal operating characteristics.  For the 
comparison with psychotherapy, inadequate covariate balance remains after propensity score 
adjustment, suggesting the potential for residual bias.  
Venlafaxine increases risk of nausea relative to SSRIs:  Amongst the two privately-insured 
populations (CCAE and Optum), we find consistent evidence of a small increased risk of nausea 
between new users of venlafaxine and the most prevalent SSRIs – sertraline, escitalopram, and 
citalopram.  When comparing the risk of nausea between new users of venlafaxine and 
sertraline in the CCAE database, the estimated calibrated HR is 1.07 (95% CI: 0.91-1.26), and 
Optum returns a similar effect estimate [HR=1.10 (95% CI: 1.00-1.22)].   When comparing the 
risk of nausea between new users of venlafaxine and escitalopram, the estimated calibrated HR 
in CCAE is HR=1.12 (95% CI: 1.01-1.25) and in Optum is HR=1.12 (95% CI: 0.97-1.30).  When 
comparing the risk of nausea between new users of venlafaxine and citalopram, the estimated 
calibrated HR in CCAE is HR=1.08 (95% CI: 1.00-1.18) and in Optum is HR=1.05 (95% CI: 0.95-
1.18).  Across all databases, comparisons between venlafaxine and each SSRI demonstrate 
sufficient clinical equipoise, adequate covariate balance, and empirical calibration restores 
nominal operating characteristics.  Compared with the clinical trial results, the observational 
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studies have a lower incidence of nausea, and are directionally consistent but had a small 
magnitude of effect estimate. 
No difference in nausea between duloxetine and paroxetine or fluoxetine:  All four databases 
produce estimates comparing the duloxetine with fluoxetine, all of which consistently 
suggested no association.  In CCAE, when comparing the risk of nausea between new users of 
duloxetine and fluoxetine, the estimated calibrated HR is 0.93 (95% CI: 0.79-1.12).  Relative to 
paroxetine, the estimated calibrated HR is 1.01 (95% CI: 0.85-1.19).  These observational studies 
allow the use of large samples to bound the magnitude of any potential effect to increase 
confidence in any conclusion around non-inferiority. 
Paroxetine higher rate of sexual dysfunction than fluoxetine and sertraline:  Among clinical 
trials of SSRIs, paroxetine is observed to have non-significant higher rates of sexual dysfunction 
than fluoxetine and sertraline. Across our observational databases, paroxetine is the least 
commonly used SSRI.  In our largest dataset (CCAE), there are <8000 new users used in each 
analysis.  While the review compared treatments for the broadly defined ‘sexual dysfunction’ 
outcome, we estimate effects for a more narrowly defined diagnosis of ‘decreased libido’, and 
the incidence of events is lower in observational data than reported in the trials.  When 
comparing the risk of decreased libido between new users of paroxetine and fluoxetine, the 
estimated calibrated HR is 1.40 (95% CI: 0.84-2.34), and in comparison with sertraline, the 
estimated calibrated HR is 1.39 (95% CI: 0.86-2.26).   
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Figure S1. Estimates for all control hypotheses before and after calibration
 
Figure S1. Hazard ratios and corresponding standard errors estimated through our systematic 
evidence generation process to four observational databases for our negative and positive 
controls before (top) and after (bottom) calibration. The estimates are stratified by the true 
hazard ratio. Note that due to limitations in sample size not all negative controls could be used 
to synthesize positive controls, and a small fraction of estimates could therefore not be 
calibrated. 
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Figure S2. Leave-one-out cross-validation of calibration 
To validate our confidence interval calibration procedure we use a leave-one-out cross-
validation. For each negative control and the positive controls derived from that negative 
control, we fit systematic error models using all other controls, and compute confidence 
intervals for the left-out controls with a wide range of widths. We subsequently check how 
often the confidence intervals contained the true hazard ratio. In each fold of the cross-
validation, error models are computed separately for each combination of target, comparator, 
and database. Figure S3 shows the coverage as a function of width of the confidence interval, 
stratified by the true hazard ratio. 
 
Figure S2. Coverage of confidence intervals, per width of the confidence interval, and stratified 
by true hazard ratio.  
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Figure S3. Comparison of results from RCTs and our observational study 
 
Figure S3. Effect size estimates on Sertraline compared to various other drugs for the outcome 
of diarrhea. Estimates from RCTs are those reported in Cipriani et al (2010). Observational 
estimates are the hazard ratios and 95% calibrated confidence intervals generated in our study. 
 
 
